Why is Infinity Pharmaceuticals, Inc. ?
Unrated Stock - No Analysis Available
Quality key factors
Factor
Value
Sales Growth (5y)
-15.60%
EBIT Growth (5y)
-6.70%
EBIT to Interest (avg)
-30.15
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.82
Sales to Capital Employed (avg)
0.07
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
35.81%
ROCE (avg)
0
ROE (avg)
0
Valuation Key Factors 
Factor
Value
P/E Ratio
Industry P/E
Price to Book Value
EV to EBIT
-0.73
EV to EBITDA
-0.74
EV to Capital Employed
-4.59
EV to Sales
11.96
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
109.47%
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
Bollinger Bands
Sideways
Sideways
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Technical Movement
Not enough Data to analyse Financial Trend
Not enough Data to analyse Financial Trend
Here's what is working for Infinity Pharmaceuticals, Inc.
Net Profit
Higher at USD -21 MM
than preceding 12 month period ended Jun 2023MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (USD MM)
Operating Cash Flow
Highest at USD -38.89 MM
in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Here's what is not working for Infinity Pharmaceuticals, Inc.
Cash and Eqv
Lowest at USD 43.48 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents






